









Markets
/
Stocks
/
nasdaq-bjdx
/

Bluejay Diagnostics Inc

BJDX

1.460USD

-0.060-3.95%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

2.18MMarket Cap

LossP/E TTM



Bluejay Diagnostics Inc

1.460

-0.060-3.95%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Despite a weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

278 / 506

Overall Ranking

466 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a rapid, near-patient testing system for triage and monitoring of disease progression. Its product candidate, an IL-6 Test for sepsis triage, is designed to provide results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and better triage/treatment decisions. The Symphony platform is a combination of its intellectual property (IP) and exclusively licensed and patented IP that consists of a mobile device and single-use test cartridges. The Symphony platform and its initial biomarker test, Symphony IL-6 test, is suited to address a subset of the global in vitro diagnostics devices market, including sepsis, cardio-metabolic diseases, cancer and other diseases that require rapid tests. Symphony targets critical care markets where physicians must quickly determine patient acuity to identify optimal treatment regimens.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 267.47.

Overvalued

The company’s latest PE is 0.00, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 13.33K shares, decreasing 45.71% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 0.00 shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.31, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.31

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.57

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.47

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

4.38

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.15

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 7.05, which is higher than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is 0.00, which is -413.89% below the recent high of -0.01 and 12638.89% above the recent low of -0.45.

Score

Industry at a Glance

Previous score

7.05

Change

0.04

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 278/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.03.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 1.02, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 1.68 and the support level at 1.32, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

1.02

Change

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.026

Buy

RSI(14)

49.075

Neutral

STOCH(KDJ)(9,3,3)

41.315

Sell

ATR(14)

0.082

High Vlolatility

CCI(14)

20.100

Neutral

Williams %R

58.065

Sell

TRIX(12,20)

0.229

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

1.520

Sell

MA10

1.494

Sell

MA20

1.445

Buy

MA50

1.485

Sell

MA100

1.614

Sell

MA200

2.655

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 0.89%, representing a quarter-over-quarter decrease of 22.59%. The largest institutional shareholder is James Simons, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Sabby Management, LLC

-100.00%

Armistice Capital LLC

6.95K

L1 Capital Global Opportunities Master Fund Ltd.

2.68K

Tower Research Capital LLC

1.74K

+213.90%

Lana Management & Business Research International LLC

511.00

UBS Financial Services, Inc.

812.00

-58.25%

Wurth (Douglas Clark)

414.00

Chase (Donald R)

98.00

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.01, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.51. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.